Table I.
Characteristics of patients with metastatic uroethelial cancer.
| Characteristic | All patients (n=100) | ECOG PS 0–1 (n=80) | ECOG PS 2 (n=20) |
|---|---|---|---|
| Gender | |||
| Male | 72 (72) | 60 (75) | 12 (60) |
| Female | 28 (28) | 20 (25) | 8 (40) |
| Age, years | |||
| Median | 68 | 68 | 68 |
| Range | 45–80 | 45–81 | 46–79 |
| Primary tumor location | |||
| Bladder | 84 (84) | 66 (85) | 15 (75) |
| Upper urinary tract | 16 (16) | 11 (14) | 5 (15) |
| Urethra | 2 (2) | 1 (1) | 0 (0) |
| Metastatic site | |||
| Lymph nodes | 66 (66) | 55 (69) | 11 (55) |
| Lung | 48 (48) | 35 (44) | 13 (65) |
| Liver | 25 (25) | 20 (25) | 5 (25) |
| Bone | 18 (18) | 14 (18) | 4 (20) |
| Other | 17 (17) | 14 (18) | 3 (15) |
| Visceral metastases | |||
| No | 24 (24) | 22 (28) | 3 (15) |
| Yes | 76 (76) | 58 (72) | 17 (85) |
| ECOG PS | |||
| 0 | 30 (30) | 30 (38) | – |
| 1 | 50 (50) | 50 (62) | – |
| 2 | 20 (20) | – | 20 (100) |
| GFR, ml/min | |||
| Median | 58 | 59 | 58 |
| Range | 21–124 | 27–124 | 21–100 |
| <10 g/dl Hb | 39 (39) | 25 (34) | 11 (50) |
| Primary curative treatment | |||
| Primary surgery | 40 (77) | 33 (77) | 7 (78) |
| Primary radiotherapy | 12 (23) | 10 (23) | 2 (22) |
| Perioperative chemotherapy | 14 (27) | 10 (23) | 4 (44) |
| Total | 52 (52) | 43 (54) | 9 (45) |
| Prior chemotherapy | |||
| Cisplatin/gemcitabine | 76 (76) | 63 (82) | 12 (67) |
| Carboplatin/gemcitabine | 17 (17) | 14 (18) | 4 (22) |
| Other | 2 (2) | 0 (0) | 2 (11) |
| Chemotherapy cycles prior to vinflunine, n | |||
| Median | 6 | 6 | 6 |
| Range | 0–20 | 0–20 | 0–16 |
All data, excluding age, GFR and cycles prior to vinflunine, is presented as n (%). ECOG PS, Eastern Cooperative Oncology Group performance status; GFR, glomerular filtration rate; Hb, hemoglobin.